Kevin Munnelly, Can "Jon" Özbal Promoted to Lead Continued OpenArray™ and RapidFire™ Division Growth
Woburn, MA, February 5, 2008 - BioTrove, Inc. today announced the promotions of Kevin Munnelly and Can "Jon" Özbal, Ph.D. to Vice President and General Manager of the company's OpenArray™ and RapidFire™ divisions, respectively. Reflecting their contributions to recent company growth, Mr. Munnelly and Dr. Özbal are the latest additions to BioTrove's senior management team.
"Both Kevin and Can have dedicated themselves to opening new doors for researchers in industry, government and academia with the OpenArray and RapidFire platforms, and were instrumental in the success of our recent deals with Applied Biosystems, Agilent Technologies, the U.S. Centers for Disease Control, top pharmaceutical companies, and many more," said Albert A. Luderer, Ph.D., President and CEO, BioTrove. "Their unflagging energy and commitment to customers and colleagues alike have shaped this company and we are confident their continued leadership will result in continued growth."
Both Mr. Munnelly and Dr. Özbal bring to their new positions significant industry experience, including recent successes with BioTrove.
With over 15 years experience in molecular biology, chemistry, software, instrument development, and statistical analysis, Mr. Munnelly joined BioTrove in 2005, serving as both OpenArray Business Unit Manager and Senior Director in the Genomics Products division. Prior to BioTrove, he was senior manager of the Platform Technology group at Millennium Pharmaceuticals, and also served as a scientist with Applied Biosystems, where he was involved in the development and commercialization of multiple life science research technologies.
Dr. Özbal, a member of the original BioTrove team, is responsible for much of the RapidFire™ Lead Discovery development. His extensive background includes bioanalytical chemistry, chromatography, and instrumentation design experience. Dr. Özbal's interest in customizing technology to meet research needs was first sparked through his doctoral work in toxicology at the Massachusetts Institute of Technology (MIT), which required the development of new instrumentation and ultra-sensitive analytical methods. Prior to joining BioTrove, Dr. Özbal was an instructor in the Division of Bioengineering and Environmental Health, now part of the Department of Biological Engineering, at MIT.
"As a company committed to providing solutions for our customers' toughest research puzzles, Kevin and Can's dedication make them exemplary members of our team," said Robert H. Ellis, Executive Chairman and President of International Operations and Research Strategy, BioTrove.
"As our business grows, Kevin and Can will continue to play a key role in guiding the development of our two technology platforms."
Mr. Munnelly holds an A.B. with honors from Bowdoin College in Biochemistry and Molecular Biology and an MBA, Magna Cum Laude, from Babson College. Dr. Özbal holds an A.B. with honors from Bowdoin College and a Ph.D. in Toxicology from MIT.
About BioTrove, Inc.
BioTrove, Inc. offers two innovative technology platforms: RapidFire™, which enables the acceleration of drug discovery and pipeline decisions, and OpenArray™, which advances genomic research in a wide range of life science fields, including agriculture, disease research, bio-defense, and public health. With more than half of the world's ten largest pharmaceutical companies as clients, and partnerships with prestigious research and public health centers around the world, BioTrove's products and services ensure that an industry committed to accuracy and speed can meet business goals.
RapidFire™ Mass Spectrometry (RFMS) uses an innovative microfluidic technology to facilitate analysis at faster than 10 seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RFMS is routinely used in many applications including the high-throughput screening of previously intractable drug targets, cytochrome P450 inhibition and other ADME assays and directed evolution studies.
The OpenArray™ Platform enables genomics researchers to generate SNP and real time qPCR data in the hundreds of thousands of data points per day, significantly increasing the number of samples analyzed while significantly decreasing the time and cost required. The flexible format and nanoliter scale of the OpenArray™ system allows for easy adjustment of sample and assay numbers, achieving economical, high-throughput genomics.
For more information, please visit www.biotrove.com or contact:
Dr. Albert Luderer, President and CEO
BioTrove, Inc.
781-721-3648
info@biotrove.com
Arielle Bernstein
Makovsky + Company
212-508-9643
abernstein@makovsky.com
|
